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Abstract
Selenoproteins have been recognized as modulators of
brain function and signaling. Phospholipid hydroperoxide
glutathione peroxidase (GPx4/PHGPx) is a unique mem-
ber of the selenium-dependent glutathione peroxidases
in mammals with a pivotal role in brain development and
function. GPx4 exists as a cytosolic, mitochondrial, and
nuclear isoform derived from a single gene. In mice, the
GPx4 gene is located on chromosome 10 in close proxi-
mity to a functional retrotransposome that is expressed
under the control of captured regulatory elements. Elu-
cidation of crystallographic data uncovered structural
peculiarities of GPx4 that provide the molecular basis for
its unique enzymatic properties and substrate specificity.
Monomeric GPx4 is multifunctional: it acts as a reducing
enzyme of peroxidized phospholipids and thiols and as
a structural protein. Transcriptional regulation of the dif-
ferent GPx4 isoforms requires several isoform-specific
cis-regulatory sequences and trans-activating factors.
Cytosolic and mitochondrial GPx4 are the major isoforms
exclusively expressed by neurons in the developing
brain. In stark contrast, following brain trauma, GPx4 is
specifically upregulated in non-neuronal cells, i.e., reac-
tive astrocytes. Molecular approaches to genetic modi-
fication in mice have revealed an essential and
isoform-specific function for GPx4 in development and
disease. Here we review recent findings on GPx4 with
emphasis on its molecular structure and function and
consider potential mechanisms that underlie neural
development and neuropathological conditions.
Keywords: apoptosis; embryogenesis; excitotoxicity;
glial cells; oxidative stress; phosphoinositides;
selenium.
Introduction
Molecular biology and bioinformatics have recently
revealed at least 25 selenoproteins, five of which are glu-
tathione peroxidases (GPxs) (Kryukov et al., 2003; Utomo
et al., 2004). All selenoproteins with known enzymatic
activity bear a selenocysteine at their active center that
is essential for catalytic activity and cannot simply be
replaced by a cysteine residue. The first mammalian sele-
noprotein was identified by Mills (1957) as the 85-kDa
classical GPx or GPx1. Subsequently, additional GPx iso-
zymes were uncovered and today the GPx family com-
prises seven well-characterized members, all of which
except two (GPx5 in humans and mice and GPx7) con-
tain a selenocysteine as the catalytically active amino
acid. The presence of selenocysteine at the active site
confers a more rapid reaction with peroxide substrates,
which make peroxidase catalysis much more efficient
(Nauser et al., 2006). On the other hand, there is an
evolutionary disadvantage for selenocysteine-containing
proteins. The amino acid selenocysteine (U), which is
required for biosynthesis of mammalian selenoenzymes,
does not have a separate codon on the genomic level.
Instead, it is encoded by a TGA-opal codon (Castellano
et al., 2004), which usually terminates translation (stop
codon). However, in mammals premature termination of
translation is counteracted by protein binding to the sele-
nocysteine insertion sequence (SECIS), which is localized
in the 59-untranslated region of the mRNA.
GPx4 is a peculiar member of the GPx family because
of its structural and functional characteristics. Whereas
GPx1, GPx2, and GPx3 act as homo-oligomeric proteins,
GPx4 is a 19–22-kDa monomeric protein. First described
by Ursini et al. (1982), GPx4 was later comprehensively
characterized with respect to its enzymatic properties
(Maiorino et al., 1990). GPx4 is unique in its tissue dis-
tribution and specificity for reducing agents (Zhang et al.,
1989; Brigelius-Flohe, 1999). This enzyme accepts many
reducing substrates in addition to glutathione and can
react with a wide array of organic and inorganic perox-
ides. In particular, its ability to directly reduce phospho-
lipid hydroperoxides within biomembranes and lipo-
proteins makes GPx4 unique among antioxidative
enzymes (Thomas et al., 1990; Sattler et al., 1994). More-
over, recent data suggest a role for GPx4 as a structural
protein (Ursini et al., 1999) and as a regulator of apop-
tosis (Nomura et al., 1999), gene expression (Brigelius-
Flohe, 2006) and eicosanoid biosynthesis (Weitzel and
Wendel, 1993). Whether the catalytic activity of the
enzyme is required for all these biological functions
remains to be investigated.
Selenoprotein expression is transcriptionally depend-
ent on selenium supply and thus there is competition
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Figure 1 Structure of the gpx4 gene and encoded isoenzymes.
Exons 2–7 encode for the C-terminal peptide, which is shared by all three GPx4 isoforms. The N-terminal sequences of c- and
m-GPx are encoded by the first exon (E1a), whereas the alternative first exon (E1b) encodes the N-terminal part of n-GPx4, including
the nuclear import sequence. Boxed areas above and below the genomic scheme indicate the corresponding mRNA. Adapted with
modifications from Borchert et al. (2003).
between various selenoproteins for the cellular selenium
pool (Brigelius-Flohe et al., 2001; Savaskan et al., 2003).
Some selenoproteins such as GPx4 and Dio3 are
expressed at normal levels, even under selenium restric-
tion, and rank high in the selenoprotein synthesis hier-
archy. In contrast, expression of other selenoproteins,
such as GPx1, is rather sensitive towards selenium short-
age and their expression is quickly downregulated when
selenium becomes limiting. This peculiarity of selenopro-
tein biology suggests that high-ranking selenoproteins
may play a more essential role in the organism (Novo-
selov et al., 2005). Although the underlying mechanism
of selenoprotein expression hierarchy is not fully eluci-
dated, mRNA stability has been proposed as a regulation
level (Weiss-Sachdev and Sunde, 2001; Muller et al.,
2003). In the case of the low-ranking GPx1 it has been
shown that nonsense-mediated decay causes degrada-
tion of the mRNA molecule under selenium deficiency.
For GPx4 the hypothesis that highly ranked selenopro-
teins are of major biological relevance is supported by
functional inactivation of gpx4 in mice. Stem cell knock-
out of gpx4 leads to early embryonic lethality (Imai et al.,
2003; Yant et al., 2003), whereas GPx1 knockout mice
develop normally and are fully viable (Ho et al., 1997; de
Haan et al., 1998). Interestingly, GPx4 shows a unique
cellular distribution in brain compared to GPx1 (Ho et al.,
1997; Schweizer et al., 2004; Savaskan et al., 2007). Dur-
ing embryonic development, GPx4 is expressed in prin-
cipal neurons of the brain.
Various aspects of GPx4 research are discussed in the
current literature (Brigelius-Flohe, 1999; Kuhn and Bor-
chert, 2002; Imai et al., 2003), but not the structural bio-
logy of GPx4 nor its role in the central nervous system.
Recent advances in these fields, including elucidation of
the crystal structure of various GPx isoforms and novel
data on regulation in response to brain injury (Borchert
et al., 2006; Savaskan et al., 2007), prompted us to crit-
ically discuss the state of the art in these fields. We also
address the role of GPx4 in neuronal signaling and dis-
cuss future developments in GPx4 research.
Coding multiplicity of GPx4 isoforms
The completion of the human genome project indicated
the presence of a single GPx4 gene mapped to chro-
mosome 19 (Kelner and Montoya, 1998). Including the
39- and 59-flanking regions, gpx4 spans approximately
4 kbp and consists of seven exons and six introns (Figure
1). This genomic organization, including exon-intron
boundaries, is well conserved among mammalian spe-
cies. In mice the GPx4 gene is located in a syntenic
region on chromosome 10 (Knopp et al., 1999). In addi-
tion to the paraloguous GPx4 gene, two retro-transposed
pseudogenes have been identified in the murine genome
of various strains with different phylogenetic states (Bos-
chan et al., 2002). One of them was mapped to chro-
mosome 10 in proximity to the paraloguous gene and is
expressed under the control of captured regulatory ele-
ments. In contrast to the second retrotransposon, which
is heavily mutated, this pseudogene does not contain
major mutations and its expression may thus lead to a
functional enzyme.
There are three distinct GPx4 isoforms: cytosolic, mito-
chondrial, and nuclear. Cytosolic GPx4 (c-GPx4, 19 kDa)
originates from gpx4 starting from the second 59-ATG
(c-ATG) of the first exon (Figure 1). In contrast, for mito-
chondrial GPx4 (m-GPx4), which has a somewhat higher
molecular weight, the first 59-ATG (m-ATG) of the first
exon is used as the translation initiation site. The addi-
tional sequence of 192 nt between these two ATGs of
exon 1 encodes a targeting sequence for mitochondria
(Arai et al., 1996). The targeting sequence is cleaved
off in the mitochondrion so that both GPx4 isoforms
An emerging role for GPx4 in the brain 1009
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Figure 2 Functional multiplicity in the regulation of the three GPx4 isoforms (m-GPx4, c-GPx4 n-GPx4).
The location of the three major transcriptional start sites (q1 bp,q192 bp andq547 bp) are identified (Nam et al., 1997; Knopp et
al., 1999; Moreno et al., 2003). Translation start sites are indicated for each isoform: m-ATG for m-Gpx4 (q145 bp), c-ATG for
c-GPx4 (q226 bp) and n-ATG for n-GPx4 (q561 bp). Functional cis-regulatory elements and their relative positions within the proximal
promoter regions are shown as small dark gray boxes. msmitochondrial; cscytosolic; nsnuclear.
(c-GPx4 and m-GPx4) cannot be differentiated on the
basis of their primary structure. This genetic constellation
raises the question as to how expression of these two
isozymes is controlled. In principle, there are two possi-
ble scenarios:
1. Translational mechanism: the major transcriptional
product of the GPx4 gene is the m-GPx4 messenger,
which is translated to the corresponding protein when
the first 59-AUG serves as the translation initiation
site. When the 59-AUG is functionally silenced, the
second 59-AUG may be recognized as the start codon
and the c-GPx4 message will be synthesized. Thus,
a switch in isoform specific expression could be
explained by functional silencing.
2. Transcriptional mechanism: multiple initiation sites for
transcription of the GPx4 gene exist, leading to iso-
form-specific messages. When a transcriptional initi-
ation site upstream of the 59-ATG is utilized, an
m-GPx4 messenger containing both AUGs (m-AUG
and c-AUG) from exon 1 is synthesized. Since the
translational machinery usually scans the 59-UTR for
the first available AUG in the mRNA, translation of
m-GPx will be initiated. In contrast, when the tran-
scriptional initiation site is located between the first
m-ATG and the downstream c-ATG, the resulting
message only contains the c-AUG and thus solely the
c-GPx4-specific isoform can be translated.
Although the translational mechanisms cannot be
completely excluded, there is no evidence of selective
silencing of the m-AUG on the translational level. In con-
trast, several lines of experimental evidence argue for
transcriptional mechanisms of isoform-specific expres-
sion regulation: (i) multiple mRNA species for GPx4 were
found (Pushpa-Rekha et al., 1995; Nam et al., 1997;
Knopp et al., 1999; Moreno et al., 2003) and at least one
of them starts between the 59- and the 39-ATG of the
GPx4 gene (Figure 1). (ii) Isoform-specific profiles of
GPx4 mRNA species during murine brain development
show similar amounts of m-GPx4 and c-GPx4 during
early stages of embryonic development (embryonic days
E6.5–E15.5). However, in later developmental stages
(E16.5) and after birth, the concentration of the m-GPx4
messenger decreased, whereas c-GPx4 mRNA remained
unchanged (Borchert et al., 2006). Such mRNA expres-
sion kinetics indicates transcriptional regulation. (iii) While
in most mammalian tissues expression of the c-GPx4
isoform is predominant, in testis the m-GPx4 messenger
is prevalent, suggesting transcriptional regulatory events.
During late spermatogenesis the nuclear isoform
(n-GPx4) is predominantly synthesized, which involves
transcription of an alternative exon localized in the first
intron of the GPx4 gene. This alternative exon (Figure 1)
encodes for an Arg-rich nuclear insertion sequence,
which is retained with the protein even after nuclear
import (Pfeifer et al., 2001). This isoenzyme has an
apparent molecular mass of approximately 34 kDa and
is specifically expressed in late spermatocytes, but was
not detected in most other cells and tissues. The nuclear
insertion sequence of n-GPx4 shows a high degree of
similarity to other nuclear import sequences, but the
mechanism of nuclear import has not been studied in
detail so far. It remains unclear what biological role this
protein may play in spermatogenesis, since mice lacking
this GPx4 isoform develop normally, are fertile and do not
show any morphological and functional defects. How-
ever, cells isolated from these mice show delayed chro-
matin condensation and this observation has been
related to the sulfhydryl oxidase activity of n-GPx4 (Con-
rad et al., 2005).
Molecular mechanisms of GPx4 transcription
regulation
The molecular mechanisms causing the complex iso-
form-specific expression patterns of GPx4 in different tis-
sues are not fully understood, but significant progress
has been made in this field during recent years. The close
proximity of the translational and transcriptional initiation
sites for m- and c-Gpx4 within exon 1a suggests at least
partially overlapping promoter regions and a high degree
of interaction between regulatory elements (Figure 2).
Functional binding of nuclear factor Y (NF-Y) was initially
shown for the proximal promoter region of the human
GPx4 gene (Huang et al., 1999). The corresponding bind-
ing motif CCAAT is conserved and functional in the
murine promoter sequence (Ufer et al., 2003). In addition,
functional binding of NF-Y to a second CCAAT element
and of stimulating protein 1 (Sp1) to three GC-rich motifs
was confirmed in the proximal promoter region of the
murine gene (Ufer et al., 2003). This is of particular inter-
est in the context of neurobiology, since these transcrip-
tion factors are active in developing neurons and reactive
astrocytes (Benfante et al., 2005; Bannwarth et al., 2006;
Mao et al., 2006). In an attempt to define minimal pro-
moter regions for m- and c-GPx4, various reporter gene
assays revealed a complex network of functional inter-
actions between cis- and trans-regulatory elements (Ufer
1010 N.E. Savaskan et al.
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Figure 3 Catalytic cycle of the GPx reaction.
Mechanistic details are described in the text.
et al., 2003; Imai et al., 2006). However, the mechanisms
that control the differential selection and strength of tran-
scription initiation sites specific to the GPx4 isoforms
remain elusive, since neither spatial arrangements of the
transcription initiation complex within the GPx4 promoter
nor far distance enhancers or silencers have been ana-
lyzed so far. Moreover, the mechanisms that are involved
in the massive upregulation of GPx4 in spermatogenic
cells and in reactive astrocytes in the brain are still not
fully understood.
The putative promoter of n-GPx4 is located within
intron 1a, in a region where several functional cis-regu-
latory elements (Sp1, Egr1, GATA, SRE, USF and CRE)
have been identified (Borchert et al., 2003). In spermatoid
cells, CRE was confirmed to bind the transcription factor
cAMP-response element modulator (CREM), which is
believed to mediate the specific onset of expression for
n-GPx4 (Tramer et al., 2004). In somatic cells recombi-
nant CREM expression is able to confer promoter activity
to the potential promoter region of intron 1a using report-
er gene assays (Tramer et al., 2004). However, in somatic
cells, no major promoter activity was found within intron
1a. Instead, this genomic fragment apparently inhibited
the proximal promoter activity (located upstream of exon
1a) (Borchert et al., 2003). The mechanistic basis for this
apparent inhibition has not been investigated in detail.
Another study reported promoter activity of sequences
in exon 1b in vitro comparable to the region upstream of
exon 1a (Maiorino et al., 2003). Similar promoter activities
were identified in the proximal portions of intron 1a,
although n-GPx4 expression is more than two orders of
magnitude lower than that of c- and m-GPx4 (Maiorino
et al., 2003; Imai et al., 2006). Thus, on a quantitative
basis it seems to be unlikely that results from the in vitro
reporter assays adequately mirror the complex regulatory
network of isoform-specific GPx4 expression in vivo. It is
more likely to be an interplay of a variety of cis-regulatory
elements clustered in the 59-flanking region of the GPx4
gene (Figure 2). To control isoform-specific GPx4 expres-
sion, the pattern of trans-acting proteins binding to the
59-region of gpx4 (including the 59-flanking region, exon
1, intron 1a, and alternative exon 1 and intron 1b) at a
given time point is likely to decide which and how strong-
ly a particular GPx4 isoform is expressed. Whether
expression of n-GPx4 is driven by a separate promoter
within intron 1a in vivo and whether additional mecha-
nisms are employed in various tissues remain to be
answered. This is of particular interest in light of the
recent finding that expression of m-GPx4 and n-GPx4
appeared to be coupled during embryonic development
and thus might be controlled by joint regulatory mecha-
nisms (Borchert et al., 2006). In contrast, c-GPx4, which
seems to share regulatory elements of transcription with
m-GPx4, exhibits different expression kinetics (Borchert
et al., 2006).
To comprehensively understand the regulation of GPx4
expression, post-transcriptional events should be con-
sidered. Post-transcriptional modifications such as alter-
native splicing of joint GPx4 mRNA precursors have
previously been suggested as factors in GPx4 regulation
on the basis of different signaling stimuli or developmen-
tal stages (Kuhn and Borchert, 2002; Tramer et al., 2002;
Borchert et al., 2003; Puglisi et al., 2003; Sneddon et al.,
2003). Post-transcriptional mechanisms conferred by the
39-untranslated region that contains the selenocysteine
insertion sequence have been studied in more detail. This
sequence element is involved in the co-translational
incorporation of selenocysteine into the nascent poly-
peptide chain (Copeland et al., 2000, 2001) and seems
to be essential but not exclusive in the regulation of
mRNA stability in the case of selenium deficiency (Bri-
gelius-Flohe, 1999; Muller et al., 2003).
Despite these insights, the complex network of tissue-
and isoform-specific expression of GPx4 is far from
completely understood and more work is needed to
determine the molecular interactions of pre-transcription-
al, transcriptional and post-transcriptional processes.
Moreover, epigenetic regulatory mechanisms of expres-
sion, such as DNA and histone modification impacting
nucleosome structure, as well as mRNA-protein interac-
tion at the 59-UTR, have not been studied in detail.
Molecular enzymology and structural aspects
of GPx4
GPx4 is a monomeric protein with a molecular mass of
approximately 20 kDa that does not undergo major post-
translational modification (Roveri et al., 1994). The cata-
lytic selenocysteine residue at position 46 (U46) is
essential and mutation of this amino acid to a cysteine
(U46C) strongly impairs the catalytic efficiency (Maiorino
et al., 1995; Schnurr et al., 2000). Kinetic analysis of the
GPx reaction suggested a tert-uni ping pong mechanism,
which involves redox shuttling of the selenocysteine
(Ursini et al., 1982). The catalytic cycle consists of three
consecutive elementary reactions (Figure 3). The first
step involves oxidation of the dissociated selenol by the
hydroperoxy substrate, yielding a selenenic acid deriva-
tive. In the second step, the oxidized enzyme reacts with
a thiol group, preferentially reduced glutathione. In the
resulting intermediate, the glutathione molecule may be
bound covalently with its sulfur to the selenium. The last
An emerging role for GPx4 in the brain 1011
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Figure 4 Crystal structures of human GPx4.
The PDB entry 2GS3 was used for structural modeling. The cat-
alytic triad (G46, Q81, W136) is indicated in green. Numbering
of amino acid residues is adjusted to the native Sec-containing
human GPx4. The four a-helices are in red, and seven b-strands
are shown in yellow.
step of the catalytic cycle involves regeneration of the
reduced enzyme by a second glutathione molecule,
which splits the transient seleno-disulfide bridge, yielding
one oxidized glutathione disulfide molecule. Compared
to other GPx isoenzymes, GPx4 exhibits three unique
enzymatic and structural properties:
1. The enzyme exhibits broad substrate specificity. In
contrast to other GPx isoforms, GPx4 is capable of
reducing complex lipid peroxides, even when in highly
structured lipid-protein assemblies, such as biomem-
branes and lipoproteins (Thomas et al., 1990; Sattler
et al., 1994; Schnurr et al., 1996).
2. Whereas other GPx4 isoforms prefer reduced gluta-
thione as a hydrogen donor, GPx4 also accepts pro-
tein thiols and other reducing equivalents, but not
thioredoxin (Maiorino et al., 2007).
3. In vivo, GPx4 is usually present as a monomeric pro-
tein. However, when expressed in large quantities it
exhibits a strong tendency for covalent protein aggre-
gation, and oxidative polymerization of GPx4 has
been implicated in the formation of the mitochondrial
capsule during spermatogenesis (Maiorino et al.,
2005).
Although these functional peculiarities have been dem-
onstrated, their structural basis is not well understood
owing to the absence of direct structural data on this
enzyme. Structural models of GPx4 have been generated
(Aumann et al., 1997; Mauri et al., 2003) based on the
X-ray coordinates of other GPx isoforms (Epp et al.,
1983; Ren et al., 1997). Although the degree of amino
acid conservation among GPx isoforms is rather low,
these models served in the past as suitable tools to pre-
dict target amino acids for site-directed mutagenesis to
impede the catalytic activity (Maiorino et al., 1995, 1998).
In retrospect, this hypothetical model adequately mir-
rored the structural features of GPx4 as indicated by
recent crystallographic data (Figure 4). The lack of direct
structural information on GPx4 until very recently is partly
attributable to the fact that no efficient natural source is
known from which the enzyme can be reliably prepared
in large quantities. Furthermore, under aerobic conditions
GPx4 rapidly undergoes protein polymerization when
expressed at higher levels, which severely hampered
enzyme crystallization. Thus, to obtain high-quality crys-
tals, expression levels had to be decreased and protein
preparation and crystallization had to be carried out
under anaerobic conditions. During the past 12 months,
five crystal structures for seleno-GPx isoforms and
selenium-free enzymes have been deposited in the
PDB database (http://www.rcsb.org/pdb/home/home.do)
including catalytically inactive U-to-G mutants of human
GPx1 (PDB entry 2F8A) and GPx4 (PDB entry 2GS3), a
U-to-C mutant of GPx2 (PDB entry 2HE3) and GPx5
(PDB entry 2I3Y). Recently we have crystallized the cat-
alytically active U46C mutant of GPx4 at resolution of
1.55 A˚ (PDB entry 2OBI; Scheerer et al., 2007). The two
X-ray data sets for GPx4 (2GS3, 2OBI) confirm that the
enzyme is a monomeric protein, in contrast to GPx1,
GPx2 and GPx5. In both X-ray structures the affinity tag
and the most N-terminal amino acids were not detected
in the electron density maps, suggesting a high degree
of structural flexibility in this part of the molecule. In gen-
eral, GPx4 shows the typical thioredoxin motif (Martin,
1995) consisting of four a-helices that are localized at the
protein surface and seven b-strands, five of which are
clustered to form a central b-sheet (Figure 4). The cata-
lytic triad consists of C46 (corresponding to U46 in the
native wild-type enzyme), Q81 and W136. This triad is
localized at a flat impression of the protein surface and
multiple site-directed mutagenesis of these residues
strongly impaired the catalytic activity of the U46C
mutant (Figure 4). Q81 and W136 are in hydrogen bond
distance to C46 and this arrangement might be important
for the catalytic activity. Although structural alignments
of GPx4 and GPx1, GPx2 and GPx5 revealed high sim-
ilarities, GPx4 shows two peculiarities. GPx4 lacks two
surface-exposed loop structures (loops 1 and 2) that
appear to increase the accessibility of the active site,
suggesting a molecular explanation for broad substrate
specificity in contrast to other GPx enzymes (Scheerer et
al., 2007). Second, surface loop 2 is lacking, which can
be considered the structural basis for the monomeric
character of GPx4. Thus, recent structural information on
GPx4 gives hints as to its unique enzymatic substrate
specificity and provides an important basis for the devel-
opment of small molecule inhibitors.
Developmental regulation and cellular
distribution in the brain
Initially, the expression of GPx4 in the central nervous
system was indicated by GPx4 activity assays, which
suggested low-level expression of the enzyme in the
brain compared to testis, liver and adrenal glands (Roveri
et al., 1994). In later studies, enzyme enriched from brain
homogenate and microsomes was tested and showed
approximately the same range of GPx activity as other
1012 N.E. Savaskan et al.
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Figure 5 Expression kinetics of the three GPx4 isoforms during brain development.
Expression levels of cytosolic, mitochondrial and nuclear GPx4 mRNAs in murine embryos and postnatal brains (N0–N4) are shown.
These data were obtained from real-time RT-PCRs normalized for GADPH mRNA levels (from Borchert et al., 2006). Note the transient
drop and overall low expression of n-GPx4 mRNA.
Figure 6 GPx4 is cell-type specifically expressed in human brain.
(A) GPx4 immunoreactive neurons in human cortex (darker grey). Immunopositive neurons are stained and show a typical pyramidal
cell shape characteristic for principal neurons (pyramidal cells). The scale bar represents 20 mm. (B) Isoform-specific expression of
GPx4 mRNA in different neuronal cells and in the brain. Note that c-GPx and m-GPx4 are the predominant transcripts in neurons
and in total brain. (Taken from Savaskan et al., 2007.)
tissues (Bourre et al., 2000). In brain mitochondria, GPx4
activity was mainly recovered in the inner mitochondrial
membrane fraction (Panfili et al., 1991). Direct evidence
of GPx4 distribution came from comparative expression
analysis, revealing onset of expression as early as during
gastrulation (Yant et al., 2003; Borchert et al., 2006). At
E6.5, all three isoforms are expressed in extra-embryonic
and embryonic structures, including the ecto-, meso-
and endoderm. During somite stage development, m-
and c-GPx4 mRNA are strongly expressed in headfold,
and in particular in forebrain, midbrain and hindbrain and
in developing eye (Borchert et al., 2006; Savaskan et al.,
2007). Throughout the rostral to caudal neural tube,
m- and c-GPx4 transcripts are detectable (Figure 5).
Although detected during embryogenesis, the nuclear
isoform is only very weakly expressed in neuroepithelium
and expression vanished at E16.5 until birth. During post-
natal development, GPx4 mRNA is mainly distributed in
cortex, hippocampus and cerebellum, indicating a neu-
ronal rather than glial origin. Hence, GPx4 expression
peaks at postnatal day 15 and gradually decreases there-
after. In fully mature adult brain, GPx4 is expressed in all
neuronal cell layers and most prominently in the hippo-
campus. Further cellular localization by means of immu-
nocytochemistry identified neurons as a major source of
GPx4 in the brain (Figure 6A; Savaskan et al., 2007).
Interestingly, GPx4 was recently identified in non-dis-
eased human brain, where it is exclusively expressed by
neurons, similar to the situation described for other mam-
malian brains (Figure 6A). Unfortunately, isoform-specific
antibodies are still not available and the current antibod-
ies recognize all three GPx4 isoforms (Borchert et al.,
2003). Thus, we developed an RT-PCR approach for the
detection and quantification of isoform-specific mRNA
species (Borchert et al., 2006). We showed that neurons
express both c- and m-GPx4 transcripts. Quantitatively,
the following expression order has been established:
c-GPx4)m-GPx44n-GPx4 (Savaskan et al., 2007).
Notably, neuronal cell lines commonly used for analysis
of neuronal differentiation and neurite growth and axon
collapse (N1E-115, PC12 and HT22) show a similar iso-
form-specific expression pattern (Figure 6B).
While these data clearly indicate neuronal expression
of differential GPx4 isoforms, the functional relevance of
the three isoforms remains open. To address this ques-
tion, various loss-of-function mutants were generated in
mice. Genetic disruption of the entire GPx4 gene in the
murine genome demonstrated that GPx4 is essential for
viability. Homozygous GPx4 knockout mice die in utero
at midgestation because of gastrulation failure (Imai et
al., 2003; Yant et al., 2003). The apparent embryonic
lethality has been related to increased apoptosis and cell
death leading to malformation of embryonic and extra-
embryonic cavities. In contrast, heterozygous GPx4 mice
are viable, fertile, and develop normally. However, these
mice are more susceptible to g-irradiation and oxidative
stress, pointing to an essential antioxidative function of
GPx4 that cannot simply be replaced by other existing
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GPxs in vivo. Mice with selective gene inactivation of
n-GPx4 are viable without any obvious neuronal failure
(Conrad et al., 2005), suggesting that m- and c-GPx4 are
required for embryogenesis in general. This is consistent
with the isoform-specific expression analysis showing
n-GPx4 mainly in testis and solely temporally expressed
in the brain (Figure 5). In line with these results, isoform-
selective gene silencing using siRNA technology dem-
onstrated that expression of both m- and c-GPx4 is
essential for normal brain development, whereas n-GPx4
is dispensable (Borchert et al., 2006). The mechanism by
which GPx4 affects neuronal development might be
related to regulation of apoptosis and neuronal differen-
tiation. Initial data indeed indicated that knockdown of
GPx4 in cultured neurons affects neuronal outgrowth and
neurite length (Savaskan and Ku¨hn, unpublished obser-
vation). Thus, m- and c-GPx4 are essential enzymes for
proper neuronal development and brain function.
An emerging role for GPx4 in neuro-
pathological conditions: cell type-specific
induction and signaling
Besides the other functions discussed, GPx4 is a multi-
functional antioxidant enzyme with anti-apoptotic pro-
perties, which relates neuronal expression to cellular
anti-oxidative defense. This is especially relevant since
neurons, in contrast to glial cells, rely essentially on their
GPx activity for clearance of free radicals and lipid per-
oxides (Dringen et al., 2005). Reactive oxygen species
(ROS) are constantly generated in neurons during physio-
logical metabolism. These reactive metabolites must be
detoxified and this process is of particular importance for
neurons, which are the primary target in degenerative
diseases. In fact, increased peroxide formation leads to
iron-catalyzed Fenton reactions with hydroxyl radical
generation. ROS, in particular hydroxyl radicals, can oxi-
dize lipids, amino-acid side chains and DNA strands,
leading to DNA strand breaks and base modifications.
Such increases in ROS levels have been found in neuro-
pathological conditions such as trauma, seizures, and
ischemia, as well as when neurons are exposed to
b-amyloid (Ab) peptides (Andersen, 2004). In fact, mice
with transgenic overexpression of GPx4 in neurons of the
cerebral cortex, hippocampus and in cerebellum are pro-
tected from oxidative injury (Ran et al., 2004). More
importantly, Ab peptide toxicity is decreased and neu-
rons survive upon expression of high levels of GPx4 (Ran
et al., 2006). This is of special relevance, since Ab toxicity
is believed to cause neuronal damage found in Alzhei-
mer’s disease (Andersen, 2004). Thus, downregulation of
neuronal GPx4 expression may render neurons more
prone to deleterious effects of oxidative damage. It has
been reported that GPx4 expression decreases H2O2 and
lipid peroxidation-induced cell death (Ran et al., 2006).
Consistent with these results, we recently found that
siRNA-mediated knockdown of GPx4 in neurons leads to
increased apoptosis and higher susceptibility to oxidative
stress (Savaskan et al., 2007). The mechanism of the
neuroprotective activity of GPx4 has not been completely
clarified. However, it has been shown that siRNA-medi-
ated knock-down of m- and c-GPx4 in neurons leads to
phosphoinositol-bisphosphate (PIP2) depletion and delo-
calization from the plasma membrane (Savaskan et al.,
2007). This process is an early event in apoptosis at the
plasma membrane and appears prior to and independent
from caspase-3 activation. Hence, GPx4 prevents exten-
sive cardiolipin oxidation, a mitochondrial phospholipid
that in its oxidized state initiates cytochrome c release
and caspase-3 activation (Nomura et al., 1999; Petrosillo
et al., 2003). GPx4 overexpression does not alter the
expression of anti-apoptosis proteins of the Bcl-2 family,
such as Bcl-2, Bcl-xL, Bax, and Bad, which would
represent the simplest explanation of the beneficial
characteristics of GPx4. In contrast, enhanced GPx4
expression could not prevent Fas-induced apoptosis in
RBL2H3 leukemia cells, indicating a certain specificity of
GPx4 in cell survival (Nomura et al., 1999). These data
can be explained by the fact that Fas-induced apoptosis
directly activates caspase-8 and does not require any
promitochondrial signals (Srinivasan et al., 1998). Thus,
GPx4 may specifically impact the signaling of mitochon-
drial apoptosis. This mechanistic evidence is supported
by findings reported on the role of GPx4 during limb
development, where expression of GPx4 is restricted to
non-apoptotic tissue and manipulation of expression
alters apoptosis patterns in tissues (Schnabel et al.,
2006). Despite these data linking GPx4 to developmental
processes, there appears to be room for GPx4 activity
independent of its anti-apoptotic character. The consti-
tutive expression of GPx4 in pyramidal and granule neu-
rons in hippocampus and cortex suggests a more
specific cellular role for the enzyme related to neuronal
function. Recent data indicate that silenced GPx4
expression in neurons affects plasma membrane PIP2
assembly and neurite growth and filopodia formation
(Savaskan et al., 2007; Savaskan and Ku¨hn, unpublished
observation). Thus, GPx4 affects PIP2-dependent plasma
membrane signaling, which represents an event affecting
synaptic transmission and other signaling pathways
unrelated to caspase activation and induction of cell
death. As shown in other tissues, GPx4 might also act
as a structural protein in the brain. Thus, expression of
catalytically inactive GPx4 enzyme in a GPx4-deficient
background would provide one good approach to deci-
pher the underlying functions of GPx4 beyond its cata-
lytic properties.
Recently, c-GPx4 has been shown to be upregulated
following brain injury (Savaskan et al., 2007). Interesting-
ly, GPx4 upregulation appears in reactive astrocytes, a
glial cell type that does not express this enzyme under
normal conditions. Following brain lesion, astrocytes
transform their cytoskeleton and migrate towards the
lesion, where they are involved in oligodendrocyte repair
and myelination, and reconstitution of the blood-brain
barrier to prevent neuroinflammation (Bush et al., 1999;
Faulkner et al., 2004). Moreover, when astrocytes are
genetically inactivated, neuronal regeneration and neurite
growth are impaired and demyelination occurs (Blain et
al., 2006; Okada et al., 2006). In this respect, GPx4
expression in astrocytes after neurotrauma might be con-
sidered as a stress response aimed at neuroprotection
to prevent further deterioration. Reactive astrocytes also
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show activation of functional cis-regulatory elements, the
corresponding binding motifs of which are functionally
present in the gene promoter region for m- and c-GPx4
(Ufer et al., 2003; Bannwarth et al., 2006; Mao et al.,
2006). Thus, astrocytic expression of c-GPx4 can be
driven by a transcriptional machinery activated following
neurotrauma. However, whether or not GPx4 has addi-
tional roles in astrocytic migration or cytoskeletal remod-
eling requires further analysis.
An intriguing link has been shown for apolipoprotein E
receptor 2 (apoER2) expression and GPx4 translation
(Andersen et al., 2003). ApoER2 is a member of the lipo-
protein receptor gene family and acts as an important
regulator of neuronal migration. In particular, apoER2
transduces signaling from the guidance molecule Reelin
and provides positional information for developing corti-
cal and cerebellar neurons (D’Arcangelo et al., 1995; Tis-
sir and Goffinet, 2003). ApoER2 deletion thus causes
massive brain formation defects, as well as male infertil-
ity, which has been related to decreased GPx4 expres-
sion (Andersen et al., 2003). Whether apoER2 and Reelin
signaling regulate GPx4 expression in the brain and
whether GPx4 expression is affected by apoER2 dele-
tion, and hence could cause the phenotype, remain to
be demonstrated. A recent report fosters the link
between apoER2 and selenoproteins. In their study,
Olson et al. (2007) showed that apoER2 functions as a
receptor for selenoprotein P (SelP), making it a likely can-
didate SelP receptor, at least in testis. Whether apoER2
in brain has the same properties and is involved in GPx4
translation has to be tested in the future.
Conclusions and perspective
Recent studies on neuronal expression of GPx4 and the
outcome of loss-of-function studies point to an essential
role for GPx4 in brain development and neuronal func-
tion. As a biocatalyst, GPx4 has been implicated in
regulation of redox-sensitive genes, in anti-oxidative
defense and in cellular apoptosis, while as a structural
protein it is involved in spermatogenesis. Regulation of
gene expression of the three GPx4 isoforms is still an ill-
defined process that involves transcriptional and post-
transcriptional regulatory elements. It is a major task for
the future to explore the exact in vivo mechanisms of
transcriptional regulation, such as chromatin remodeling,
DNA and histone modification, regulatory element iden-
tification, protein-RNA interactions and others, to put
these events into a comprehensive scheme reflecting the
whole regulatory network. A second field of intense
research is the molecular enzymology of GPx4. The
recently identified crystal structures of two GPx4 mutants
provide a solid foundation for targeted structure-based
protein design. It is now possible to address experimen-
tally detailed questions on GPx reaction (direct structural
identification of catalytic intermediates) and to investigate
the structural basis for non-covalent oligomer formation
and enzymatic peculiarities of GPx4 such as its broad
substrate specificity. This may also prompt research on
screening for small molecule ligand/inhibitor libraries. A
third emerging field of general interest is GPx4 research
in neural development and its role in the central nervous
system. In the brain, GPx4 is exclusively expressed by
neurons from early development until maturation, when
the predominant isoforms are c- and m-GPx4. Hence,
following brain trauma, GPx4 is upregulated in reactive
astrocytes, a non-neuronal cell type in the brain. Molec-
ular approaches to genetic inactivation and overexpres-
sion in mice revealed its essential and isoform-specific
function for brain development and its role in oxidative
stress and neurotoxicity, which makes GPx4 an ideal tar-
get for pharmacological approaches. Since GPx4 is part
of the selenoprotein family and has a selenocysteine in
its catalytic center, many functions of GPx4 have been
attributed to its enzymatic activity. However, it needs to
be investigated in the future whether other neurobiolo-
gical functions such as neurite growth and differentiation
are GPx4-dependent and what precise role GPx4 may
play in activated astrocytes. Ongoing studies will deci-
pher the isoform-specific signaling in neurons and will
explore the essential role of GPx4 in the brain beyond
anti-oxidative functions. It will be of major medical rele-
vance to consider potential relations between GPx4 and
common neurodegenerative and neoplastic diseases
such as Parkinson’s disease, Alzheimer disease, and
primary brain tumors.
At the time of writing, a study by Burk et al. (2007) was
published that reports on slightly lower brain selenium
levels in apoER2 knockout mice. Although the question
as to whether apoER2 regulates GPx4 expression is still
unanswered, these recent data suggest that the apoER2-/-
phenotype may also be attributed to overall altered sele-
noprotein expression in neurons and glial cells.
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